New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
07:56 EDTARIA, LLYARIAD volatility may move, Eli Lilly approached Daily Mail says
ARIAD (ARIA) option implied volatility could pick up after the U.K.'s Daily Mail said the company has been approached by Eli Lilly (LLY) regarding a possible deal, with Lilly reportedly willing to pay up to $20 per share cash for Ariad. Overall option implied volatility of 85 is below its 26-week average of 90 according to Track Data, suggesting decreasing price movement.
News For ARIA;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 29, 2015
10:53 EDTARIAOptions with increasing implied volatility
Options with increasing implied volatility: THRX ALTR ARIA DECK ANF KORS CVC CCE
10:39 EDTLLYCiti analyst says outlook still strong for big pharma
Subscribe for More Information
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:26 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:16 EDTARIAARIAD enters into settlement agreement with Sarissa Capital Management
Subscribe for More Information
07:02 EDTARIAARIAD says Harvey Berger to retire as chairman and CEO
Subscribe for More Information
06:22 EDTARIAARIAD settles with Sarissa Capital, CEO to retire by end of year
Subscribe for More Information
06:16 EDTLLYPfizer downgraded to Neutral from Buy at Citigroup
Citigroup analyst Andrew Baum downgraded Pfizer (PFE) to Neutral citing the stock's "strong" relative outperformance this year. Buam prefers prefer Eli Lilly (LLY), which he upgraded this morning to Buy, and Bristol-Myers (BMY) among large-cap U.S. Pharmaceuticals. He keeps a $37 price target for Pfizer shares.
06:13 EDTLLYEli Lilly upgraded to Buy with $100 target at Citigroup
Citigroup analyst Andrew Baum upgraded Eli Lilly to Buy from Neutral and raised his price target for shares to $100 from $66. The changes come after Baum increased his risk-adjusted peak sales estimate for Lilly's heart disease drug evacetrapib to $3.8B from $1.0B. The analyst also believes the company's oncology molecules abemaciclib and galunisertib are "high quality" and "under-appreciated." Shares of Lilly closed yesterday up 29c to $71.18.
April 27, 2015
06:19 EDTLLYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
16:29 EDTLLYEli Lilly receives fourth FDA approval for CYRAMZA
Subscribe for More Information
April 23, 2015
09:52 EDTLLYEli Lilly sees at least $200M in savings from Novartis Animal Health acquisition
09:33 EDTLLYEli Lilly sees stronger doller hurting FY15 revenue by 7.5%
Subscribe for More Information
06:27 EDTLLYEli Lilly backs FY15 adjusted EPS view of $3.10-$3.20, consensus $3.15
Subscribe for More Information
06:26 EDTLLYEli Lilly reports Q1 EPS 87c, consensus 77c
Subscribe for More Information
April 22, 2015
15:50 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
14:35 EDTLLYEarnings Watch: Lilly to report Q1 results amid patent expirations
Eli Lilly and Company (LLY) is scheduled to report first quarter earnings before the market open on Thursday, April 23 with a conference call scheduled for 9:00 am ET. Lilly is a global pharmaceutical manufacturer that also has an animal health business segment. EXPECTATIONS: Analysts are looking for earnings per share of 77c on revenue of $4.62B, according to First Call. The consensus range for EPS is 64c-99c on revenue of $4.54B-$4.7B. LAST QUARTER: Eli Lilly reported fourth quarter EPS of 75c, compared to consensus estimates of 74c, on revenue of $5.12B against estimates of $5.2B. The company said it sees fiscal year 2015 EPS of $3.10-$3.20 on revenue of $19.5B-$20B. Lilly's CEO John Lechleiter commented on the quarter, "While Lilly's fourth quarter 2014 results continue to reflect the impact of patent expirations, we are moving to a period of growth led by diabetes, oncology and animal health. Despite the loss of significant revenue for Cymbalta and Evista following the expiration of our U.S. patents, we saw strong performance from many other products. At the same time, we made excellent progress with our innovation-based strategy, and we continue to advance our pipeline." STREET RESEARCH: On March 25, Suntrust raised its price target on Lilly shares to $95 from $80. After meeting with Eli Lilly's management, SunTrust said it expects the company's oncology and diabetes sales to double over the next five years. The firm is upbeat about the short-term outlook of the company's diabetes treatment, and says that its late stage autoimmune, Alzheimer's and cardiovascular treatments are advancing, while its Alzheimer's programs remain underappreciated. SunTrust said it expects the company's earnings CAGR to be in the mid teens between 2015-2020. It kept a Buy rating on Lilly shares. PRICE ACTION: Lilly shares are relatively flat since the company's last earnings report on January 30, and are trading up fractionally to $72.40 in midday trading ahead of Thursday's earnings release.
07:38 EDTARIAARIAD issued U.S. patent on brigatinib
Subscribe for More Information
April 21, 2015
14:30 EDTARIAARIAD could be worth double current value to strategic buyer, BBJ BioFlash says
Subscribe for More Information
07:36 EDTARIAARIAD anounces results of preclinical studies on Brigatinib at AACR meeting
ARIAD Pharmaceuticals announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor, brigatinib at the American Association for Cancer Research Annual Meeting 2015. Brigatinib is in development for the treatment of patients with anaplastic lymphoma kinase positive metastatic non-small cell lung cancer, who are resistant to crizotinib. An oral presentation describes, for the first time, the design and chemical structure of brigatinib, discovered using ARIADís structure-based drug design platform. With the goal of designing a selective ALK inhibitor with broad-based activity against crizotinib-resistant mutants, ARIAD scientists advanced a series of novel compounds culminating in the identification of brigatinib. Brigatinib incorporates unique chemical-design features, including the distinctive use of a recognition element that confers favorable pharmacologic properties. Brigatinib has at least 10-fold greater potency than crizotinib against ALK+ NSCLC cell lines and was broadly active against clinically relevant crizotinib-resistant mutants in preclinical models. A poster presentation shows that brigatinib, at clinically achievable concentrations, has potent anti-tumor activity against a panel of 17 distinct ALK mutants known to confer resistance to other ALK inhibitors. In a separate study designed to model the occurrence of brain metastases in ALK+ lung cancer patients, brigatinib significantly reduced the tumor burden in mice with ALK+ brain tumors compared to the tumors in mice treated with crizotinib. Survival of brigatinib-treated mice was also markedly enhanced compared to the survival duration of crizotinib-treated mice.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use